Drug updated on 11/17/2023

Dosage FormInjection: 16.6 mg/0.416 mL, 23 mg/0.574 mL, or 32.4 mg/0.81 mL in single-dose prefilled syringes
Drug ClassComplement inhibitors
Ongoing and Completed StudiesClinicalTrials.gov


  • For the treatment of generalized myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody positive

Product Monograph / Prescribing Information

Document TitleYearSource
Zilbrysq (zilucoplan) Prescribing Information.2023Ra Pharmaceuticals, Inc

Systematic Reviews / Meta-Analyses